Log In
Print this Print this

olmutinib (BI 1482694, HM61713)

  Manage Alerts
Collapse Summary General Information
Company Hanmi Pharmaceutical Co. Ltd.
DescriptionThird-generation EGFR mutation-specific tyrosine kinase inhibitor (TKI)
Molecular Target Epidermal growth factor receptor (EGFR)
Mechanism of ActionEpidermal growth factor (EGF) receptor inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat EGFR T790M mutation-positive non-small cell lung cancer (NSCLC); Treat non-small cell lung cancer (NSCLC)
Regulatory Designation U.S. - Breakthrough Therapy (Treat EGFR T790M mutation-positive non-small cell lung cancer (NSCLC))
PartnerZai Lab Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
Get a free BioCentury trial today